Ignite Creation Date:
2025-12-24 @ 7:51 PM
Ignite Modification Date:
2025-12-25 @ 5:27 PM
Study NCT ID:
NCT04500704
Status:
UNKNOWN
Last Update Posted:
2020-08-05
First Post:
2020-08-02
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC
Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-10
Start Date Type:
ESTIMATED
Primary Completion Date:
2021-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-10
Completion Date Type:
ESTIMATED
First Submit Date:
2020-08-02
First Submit QC Date:
None
Study First Post Date:
2020-08-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-08-04
Last Update Post Date:
2020-08-05
Last Update Post Date Type:
ACTUAL